AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of August 24, 2026, ABCL trades at $10.78 with a market cap of $3.67B and a P/E ratio of -19.75. ABCL moved -6.27% today. Year to date, ABCL is +210.23%; over the trailing twelve months it is +141.69%. Its 52-week range spans $1.89 to $12.15. Analyst consensus is strong buy with an average price target of $17.17. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest ABCL news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $10.78 |
| Market Cap | $3.67B |
| P/E Ratio | -19.75 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.15 |
| 52-Week Low | $1.89 |
| Volume | 6.18M |
| Avg Volume | 0 |
| Revenue (TTM) | $66.17M |
| Net Income | $-164.66M |
| Gross Margin | 0.00% |
7 analysts cover ABCL: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.17.